21世纪经济报道记者季媛媛 2025年，中国创新药企在全球医药领域的关注度持续攀升。 一方面，国内政策大力扶持创新药物研发，从资金投入到审批流程优化，为创新药企营造了极为有利的 发展环境，吸引了大量科研人才与资本的汇聚；另一方面，随着中国药企在肿瘤、罕见病等重大疾病领 域不断取得突破，研发出一系列具有自主知识产权的创新药物，其疗效和安全性得到国际认可，使得海 外市场对中国创新药的关注与需求也日益增长，众多国际药企纷纷寻求与中国创新药企开展合作。 数据可以佐证这一现实。据国家药监局披露的数据，我国上半年批准创新药43个，同比增长59%，几乎 追平2024年全年48个的纪录。 另据麦肯锡2024年报告，中国在研药物管线的全球占比达到26.7%，位居世界第二，仅次于美国的 49.1%。此外，2024年美国FDA批准的新药中，超过一半的分子源自中国实验室，这表明中国在新药研 发领域的全球影响力显著增强。这标志着中国在创新领域的地位发生了极为显著的变化。 正如前FDA局长Scott Gottlieb所言：2025年，是属于中国生物科技的"DeepSeek时刻"。 产业端的繁荣是否也会带动资本市场？上实资本执行董事、上海 ...

Group 1 - Otsuka Medical Devices Co., Ltd. has agreed to sell approximately 291 million shares of MicroPort Medical to various buyers, including Shanghai Shenshi Capital and We'Tron Capital Limited, which represents 15.7% of MicroPort's total share capital [1] - Following the announcement, MicroPort's stock price surged, opening up 14.99% and closing with a 4.75% increase, giving it a market capitalization of approximately HKD 21.2 billion [1] - This transaction will reduce Otsuka's stake in MicroPort from 20.7% to 5%, marking the first time since 2004 that Otsuka will not be the largest shareholder [1] Group 2 - Otsuka's initial investment in MicroPort dates back to 2004 when it invested USD 18 million for a 40% stake, which has since appreciated significantly, yielding a return of nearly 31 times [2] - The current shareholder structure of MicroPort includes We'Tron Capital Limited and the Jinshan Foundation as the second and third largest shareholders, holding a combined 37.5% [2] - The fourth and fifth largest shareholders are Shanghai ZJ Hi-Tech Investment Corporation and Shanghai Zhangjiang Health Products Holdings, with a combined stake of 16.0% [2] Group 3 - The buyer, Shanghai Shenshi Capital, is a fund management platform fully controlled by the Shanghai State-owned Assets Supervision and Administration Commission, indicating renewed interest in the biopharmaceutical sector [3] - MicroPort has faced financial challenges, reporting net losses over the past five years, with losses of CNY 1.248 billion, 1.763 billion, 3.04 billion, 3.383 billion, and 1.539 billion from 2020 to 2024 [3] - Despite the losses, MicroPort's revenue has shown consistent growth, increasing from CNY 4.233 billion in 2020 to CNY 7.412 billion in 2024 [3]